China is one of the fastest-growing pharma markets in the world, yet its pricing and reimbursement systems can seem perplexing to most pharmaceutical companies trying to do business there. Now, with major healthcare reforms in the works, the rules will likely get even more complex. Join FDC-Windhover, PharmAsia News and Sidley Austin LLP on Feb. 20, 2009 for a webinar that will help you and your staff understand what’s happening in China and how to take advantage of this very lucrative market.
China’s plans for changing its healthcare system — which promises to provide universal healthcare to most citizens by 2020 — include major revisions to its essential medicines list, making it comparable to the World Health Organization’s much shorter list.
But the Chinese government has a difficult task ahead of it. It must create a balanced system that ensures access to essential medicines by its citizens and promotes the sale of novel, life-saving medicines developed by multinationals. Over the long term, it also means creating a pricing and reimbursement system that encourages innovation within the Chinese pharmaceutical industry, one of the key sectors driving China’s recent economic growth.
In this 90-minute webinar — live from Beijing and Shanghai — you’ll gain insight into China’s drug pricing and reimbursement system from legal experts who struggle with it every day. They’ll help you understand the role that local and national governments play in the process, and the principles that Chinese regulators are using to establish pricing and reimbursement standards for the products you sell there. You’ll also get the most up-to-date information on China’s planned healthcare reforms, including current status and a timeframe for implementation.
Sidley is proud to co-sponsor this FDC-Windhover webinar.
Friday, Feb. 20, 2009
9 am Eastern | 6 am Pacific | 2 pm WET | 3 pm CET